A Dual Killing Strategy - Photocatalytic Generation of Singlet Oxygen with Concomitant Pt(IV) Prodrug Activation.

A Ruthenium-based mitochondrial-targeting photosensitiser that undergoes efficient cell uptake, enables the rapid catalytic conversion of Pt(IV) prodrugs into their active Pt(II) counterparts and drives the generation of singlet oxygen was designed. This duality drives two orthogonal killing mechanisms with cytotoxicity mediated with temporal and spatial control and was shown to elicit cell death of a panel of cancer cell lines including those showing oxaliplatin-resistance.

[1]  B. Oliveira,et al.  Radical‐Mediated Thiol‐Ene Strategy: Photoactivation of Thiol‐Containing Drugs in Cancer Cells , 2018, Angewandte Chemie.

[2]  B. Oliveira,et al.  Radical‐Mediated Thiol‐Ene Strategy: Photoactivation of Thiol‐Containing Drugs in Cancer Cells , 2018, Angewandte Chemie.

[3]  Wiktor Szymanski,et al.  Photoactivation of MDM2 Inhibitors: Controlling Protein–Protein Interaction with Light , 2018, Journal of the American Chemical Society.

[4]  X. López,et al.  Riboflavin as a bioorthogonal photocatalyst for the activation of a PtIV prodrug† †Electronic supplementary information (ESI) available: Details on the methods employed, photocatalysis studies in solution and in biological environments, DFT calculations. See DOI: 10.1039/c7sc01109a Click here for ad , 2017, Chemical science.

[5]  Pengyuan Yang,et al.  Targeting Negative Surface Charges of Cancer Cells by Multifunctional Nanoprobes , 2016, Theranostics.

[6]  S. Woo,et al.  Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy. , 2016, Journal of medicinal chemistry.

[7]  S. Lippard,et al.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. , 2016, Chemical reviews.

[8]  V. Brabec,et al.  Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc04205d , 2016, Chemical science.

[9]  L. Lilge,et al.  A novel class of ruthenium-based photosensitizers effectively kills in vitro cancer cells and in vivo tumors , 2015, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[10]  E. Yavin,et al.  Platinum(IV) prodrugs with haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions. , 2013, Angewandte Chemie.

[11]  K. Moghissi,et al.  Photodynamic Therapy (PDT): PDT Mechanisms , 2013, Clinical endoscopy.

[12]  T. Hambley,et al.  Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate. , 2012, Chemical communications.

[13]  Amitava Das,et al.  Photophysical properties of ligand localized excited state in ruthenium(II) polypyridyl complexes: a combined effect of electron donor-acceptor ligand. , 2011, Dalton transactions.

[14]  P. Gramatica,et al.  Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure–activity relationship modeling , 2010, JBIC Journal of Biological Inorganic Chemistry.

[15]  T. Martin,et al.  Anti-Cancer agents in medicinal chemistry (Formerly current medicinal chemistry - Anti-cancer agents). , 2010, Anti-cancer agents in medicinal chemistry.

[16]  P. Sadler,et al.  Photoactivatable platinum complexes. , 2007, Anti-cancer agents in medicinal chemistry.

[17]  Bergein F Overholt,et al.  Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. , 2005, Gastrointestinal endoscopy.

[18]  T Theodossy,et al.  Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer , 2004, British Journal of Cancer.

[19]  John Tulip,et al.  Whole bladder photodynamic therapy for orthotopic superficial bladder cancer in rats: a study of intravenous and intravesical administration of photosensitizers. , 2003, The Journal of urology.

[20]  M. DeRosa.  Photosensitized singlet oxygen and its applications , 2002 .

[21]  A. Dabrowska,et al.  Potentiation of the anti-tumour effects of Photofrin®-based photodynamic therapy by localized treatment with G-CSF , 2000, British Journal of Cancer.

[22]  T. Hambley,et al.  Modifying the properties of platinum (IV) complexes in order to increase biological effectiveness. , 1999, Journal of inorganic biochemistry.

[23]  Sunhee Choi,et al.  Reduction and Anticancer Activity of Platinum(IV) Complexes , 1998 .

[24]  P. Speight,et al.  Photodynamic therapy using 5‐aminolevulinic acid for premalignant and malignant lesions of the oral cavity , 1996, Cancer.

[25]  P. Calzavara-Pinton,et al.  Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. , 1995, Journal of photochemistry and photobiology. B, Biology.

[26]  H Kerl,et al.  Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? , 1993, Journal of the American Academy of Dermatology.

[27]  Michele T. Cooper,et al.  Cutaneous phototoxic occurrences in patients receiving Photofrin® , 1990, Lasers in surgery and medicine.

[28]  V. Balzani,et al.  Absorption spectra, luminescence properties, and electrochemical behavior of tris-heteroleptic ruthenium(II) polypyridine complexes , 1988 .